-
Mashup Score: 2Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin for Adult Relapsed or Refractory B-Cell ALL - 5 hour(s) ago
This phase 1 dose-escalation trial examines whether inotuzumab ozogamicin plus dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) is safe and effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (ALL).
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
DDX41 germline mutations define the most common genetic syndrome predisposing to myeloid neoplasms (MN). Two papers highlight the genetic landscape and pro
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 12 day(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion - 22 day(s) ago
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion - 22 day(s) ago
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant - 1 month(s) ago
Bone Marrow Transplantation – EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation - 1 month(s) ago
Bone Marrow Transplantation – Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation - 1 month(s) ago
Bone Marrow Transplantation – A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Efficiency of Biomarker-Driven Clinical Trial Designs - 2 month(s) ago
Precision medicine involves biomarker-directed therapeutic strategies that optimize the risk-benefit ratio for each patient. Implementation of precision medicine requires biomarker-driven randomized clinical trials (RCTs) to generate reliable evidence-based assessment of all rel evant components of these biomarker-directed strategies. The increasing number of potential biomarker subgroups and the corresponding smaller number of patients in each subgroup create feasibility challenges for these designs.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 2 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial | Oncology | JAMA Oncology | JAMA Network https://t.co/MwkMmICJoK